Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Aarti Drugs, part of the Aarti group, manufactures active pharmaceutical ingredients (APIs), pharma intermediates and specialty chemicals. Its API portfolio is concentrated in antidiarrheals, antifungals, anti-inflammatories and antibiotics sold to domestic and export formulation makers, and it also produces finished formulations through its subsidiary Pinnacle Life Science. Revenue is driven mainly by bulk API volumes, making margins sensitive to raw material and China supply-chain pricing.
An established mid-tier Indian API manufacturer with leadership in select molecules such as antidiarrheal APIs.
Aarti Drugs Ltd. is a constituent of NIFTY MICROCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Aarti Drugs Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 21.36 | 18.35 | 18.56 |
| Book value / share (₹) | 169.74 | 150.03 | 139.43 |
| Return on equity | 12.6% | 12.3% | 13.4% |
| Return on capital employed | 12.8% | 13.3% | 16.2% |
| Operating margin | 9.4% | 9.7% | 10.5% |
| Net margin | 7.6% | 7.0% | 6.8% |
| EBITDA | ₹309 Cr | ₹287 Cr | ₹316 Cr |
| Free cash flow | ₹80 Cr | ₹67 Cr | ₹133 Cr |
| Total debt | ₹575 Cr | ₹612 Cr | ₹562 Cr |
| Debt to equity | 0.37 | 0.45 | 0.44 |
| Interest coverage | 7.2 | 6.5 | 7.9 |
| Current ratio | 1.59 | 1.60 | 1.66 |
| Shares outstanding | 9,12,70,000 | 9,12,70,000 | 9,19,40,000 |
Open the full income statement, balance sheet and cash flow for AARTIDRUGS →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.